A TD Ameritrade Insider Bought the Stock

Page 1 of 2

Kerry Peacock, who sits on the Board of Directors at TD Ameritrade Holding Corp. (NYSE:AMTD), directly bought 3,500 shares on January 24th at an average price of $19.08 per share. These are Peacock’s first direct holdings of TD Ameritrade stock, but she joined the Board in July 2012 and we think that is a long enough lag to make this move a legitimate insider purchase rather than a “courtesy purchase” as might happen with a new Board member. She is an officer at Toronto-Dominion Bank (NYSE:TD), which is a major shareholder in TD Ameritrade. Insider purchases can be bullish signals for a company’s stock since they represent enough confidence in higher stock prices to overcome the benefits of diversification (learn more about studies on insider trading).

TD Ameritrade Holding Corp.’s business remained steady in quarter ending December 2012 (the first of its fiscal year), with minimal changes in revenue and earnings from their levels a year earlier. A slight decrease in commissions and transactions revenue was offset by more asset-based revenues. Top and bottom lines were also more or less unchanged compared to the quarter ending in September. The stock does trades at 18 times trailing earnings, so the market is pricing in expectations of at least some growth in the coming years. Analyst expectations imply a current-year P/E of 18 as well. This is a bit concerning to us; while TD Ameritrade’s business does appear very stable, we’d generally want to see a lower earnings multiple for us to consider such a company a good value.

SAC CAPITAL ADVISORS

Billionaire Steve Cohen’s SAC Capital Advisors moved heavily into TD Ameritrade Holding Corp. during the third quarter of 2012, building what had been a very small position for the fund up to 3.7 million shares by the end of September (see more of Cohen’s stock picks). Millennium Management, which is managed by billionaire Israel Englander, also increased its stake substantially during the quarter (find Englander’s favorite stocks). Chuck Akre’s Akre Capital Management was another hedge fund holder of the stock, with 3.2 million shares in its portfolio (check out more stocks Akre Capital Management owned).

How does TD Ameritrade compare to its peers?

Page 1 of 2

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!